Drugs / Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04143061 | Dec 2019 → Jan 2023 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04143061 ↗ |
| Modality | Vaccine | “tetanus toxoid conjugate vaccine” NCT04143061 ↗ |
| Route | Intramuscular | “Route of administration: intramuscular, 0.5 mL” NCT04143061 ↗ |